Will the Australian High Court Myriad “gene patent” decision impact the patenting of all isolated biological material?

Last week, Shelston IP reported that the Australian High Court (the Australian equivalent to the US Supreme Court) unanimous ruled that isolated naturally-occurring nucleic acids were not patentable subject matter in Australia. The decision itself has been widely reported. There has, however, been little or no commentary regarding the ramifications of the decision and, in